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Abstract 
We analyze and assess BCR repertoires of SLE patients before and after high dose glucocorticoid therapy to address 
two fundamental questions: (1) After the treatment, how the BCR repertoire of SLE patient change on the clone level? 
(2) How to screen putative autoantibody clone set from BCR repertoire of SLE patients? The PBMCs of two SLE patients 
(P1 and P2) at different time points were collected, and DNA of these samples were extracted. High-throughput 
sequencing technology was applied in detection of BCR repertoire. Finally, we used bioinformatic methodology 
to analyse sequence data. We found that these two patients lost some IGHV3 family genes usage after treatment 
compared with before treatment. For pairing of IGHV–IGHJ gene, no significant change was shown for each patient. 
In addition, analyses of the composition of H-CDR3 showed overall AA compositions of H-CDR3 at three time points 
in each SLE patients were very similar, and the results of H-CDR3 AA usage that had the same length (14 AA) and the 
same position were similar. Antinuclear antibody tests of SLE patients showed that level of some antinuclear antibod-
ies reduced after treatment; however, there was no sign that the percentage of autoantibody clones in BCR reper-
toires would reduce. High dose glucocorticoid treatment in short term will have little impact on composition of BCR 
repertoire of SLE patient. Treatment can reduce the amount of autoantibody in the protein level, but may not reduce 
the percentage of autoantibody clones in BCR repertoire in the clonal level.
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Background
Systemic lupus erythematosus (SLE) is an autoimmune 
disease with unknown etiology and abnormal activation 
of B cells. Various autoantibodies can be detected in the 
serum of the SLE patients. Among these autoantibod-
ies, anti-dsDNA, anti-SM and anticardiolipin antibod-
ies have important diagnosis value (Hochberg 1997). It 
is currently considered that, autoreactive B cell and the 
autoantibodies secreted by plasmocyte are the main fac-
tors that directly resulted in pathogen of SLE (Arbuckle 
et  al. 2003). Meanwhile, B cell is also considered as the 
main target of SLE treatment (Shlomchik et  al. 2001; 
Sanz and Lee 2010).
B cell receptor (BCR), which is on the surface of B 
cell membrane, is an important functional receptor of 
B cell, involving in immune response of humoral induc-
ing. BCR is a tetrapeptide chain structure with two heavy 
chains (IGH) and two light chains (IGL). The heavy 
chain complementary determining region 3 (H-CDR3) 
is thought to be the key regions of antigen recognition 
and combination (Tonegawa 1983; Chothia et  al. 1989; 
Padlan 1994; Wilson and Stanfield 1994). As for healthy 
people, peripheral blood often contains about 3  ×  109 
BCRs, and the diversity of BCR repertoire or antibody 
repertoire is produced by multiple mechanism, mainly 
including rearrangement of various discontinuous V, 
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D and J gene segments (recombination diversity) (Jung 
et al. 2006), insertion and deletion of nucleotide at VDJ 
joint (junctional diversity) (Stewart and Schwartz 1994) 
and somatic hypermutation (SHM) after B cell entering 
peripheral region (Berek et al. 1991).
The past studies have done distinctive analysis on 
BCR gene composition and rearrangement of SLE and 
functional study on SLE autoantibody. Kasaian et  al. 
(1994) found that many VH and VL genes taken from 
anti-DNA IgA autoantibody heavy chain can improve 
the choice of its SHM. Mockridge et al. (1998) has ana-
lyzed on recombination of VH3-34 and VL gene of two 
SLE patients’ autoantibody and provided a good basis 
for studying the length and specificity of CDR3 amino 
acid (AA). In 1996, Krishnan et al. found that SLE anti-
dsDNA autoantibody was closely related to content of 
arginine of H-CDR3 (Krishnan et al. 1996), and not long 
after that, found that there was no significant difference 
in arginine usage of H-CDR3 region in anti-DNA autoan-
tibody between NZBxNZW F1 mice and BALB/c mice 
in the early stage. However, oligoclonal hyperplasia will 
gradually occur in H-CDR3 of autoantibody rich in argi-
nine in NZBxNZW F1 mice (Krishnan and Marion 1998). 
Guo et al. who studied on SLE mouse model found that 
high affinity antinuclear antibody mainly come from 
gene recombination, SHM and VH gene replacement 
of CDR3 region, and that the SHM detection of autoan-
tibody CDR3 region was very important in the study of 
SLE autoantibody development and B cell differentiation 
and could provide good monitoring points for SLE (Guo 
et al. 2010). Although anti-dsDNA and anti-APL are very 
important in SLE pathology, it is not mean that if there 
is anti-dsDNA and anti-APL, there will be clinical mani-
festation. Only there is arginine gathering in IgG CDR3 
region, there will be serious pathology lesion (Rahman 
2004).
On clinical, high dose glucocorticoid therapy has been 
widely used in SLE treatment at the active stage. How-
ever, this treatment is nonspecific, unable to distinguish 
normal cells and autoreactive cells, so as to cause large 
amount of side effects, including serious toxicity and 
damage to metabolic balance, cardiovascular system, 
eyes, and bone. Currently, it is still unclear whether this 
non-specific treatment will affect BCR repertoire of SLE 
patients. In order to overcome these side effects, some 
scholars had researched and developed B cell targeted 
drugs (some monoclonal antibodies aimed at B cell mem-
brane molecules or excreted factors). Unfortunately, B 
cell targeted therapy strategy cannot act specifically on 
autoreactive B cells. In addition, the type of SLE autoanti-
bodies is various; therefore, we recommend the clone set 
of autoantibodies is the better target of targeted therapy.
On the consideration of the listed reasons, we used 
high-throughput sequencing to make a short-term evalu-
ation on BCR repertoire of SLE patients after high dose 
glucocorticoid treatment, aiming at solving two fun-
damental problems: (1) After treatment, how the BCR 
repertoire of SLE patient change on the clonal level? (2) 
How to screen putative autoantibody clone set from SLE 
BCR repertoire? Because there were CNV (copy num-
ber variation) and germline gene variation on the IGHV 
gene locus, there is great difference in IGHVs between 
individuals (Watson and Breden 2012). Besides, SLE 
patients have great heterogeneity in clinical and serology 
manifestation. On clinical, it is suggested to conduct per-
sonalized management and treatment on SLE patients. 
Based on these reasons, the experiment we designed is 
to observe the change of same SLE patient before and 
after treatment. Generally, the renewal cycle of human 
immune cell is 28 days, so we chose the first month after 
treatment as the first time point after treatment. On the 
basis of this, we further track the prognosis condition of 
the patients at the third month after treatment.
Methods
Subjects
Following the principle of informed consent and under 
a protocol approved by local Ethics committee, we col-
lected the peripheral blood samples of 2 SLE patients that 
are provided by Department of Nephropathy and Rheu-
matology of Zunyi Medical University affiliated hospital. 
SLE patients were diagnosed according to the standard 
proposed by American College of Rheumatology in 2011 
and those during gestation or lactation period and those 
with infections or serious primary disease of heart, liver, 
renal, brain and hemopoietic system or other autoim-
mune disease were eliminated. The result codes of three 
time points, before treatment, 1  month after treatment 
and 3  months after treatment, of P1 (female, 45  years 
old, recurrent lupus nephritis) were defined as P1-0, P1-1 
and P1-3. Similarly, P2-0, P2-1 and P2-3 represented 
the result of these three time points of patient P2 (male, 
20  years old, primary lupus nephritis), respectively. The 
basic information of patients was presented in Additional 
file  2: Table S1. These two patients both received high 
dose glucocorticoid therapy (≥500 mg).
Preparation of sample
Ficoll lymphocyte separation medium (Beijing Solarbio 
Science and Technology Co., Ltd, Cat. No. P8610) and 
density gradient centrifugation were used in this process. 
Peripheral blood mononuclear cells (PBMCs) of every 
patient at different time points were separated. QIAamp 
DNA MiniKit (Cat. No. 51304, QIAGEN) was used to 
Page 3 of 10Shi et al. SpringerPlus  (2016) 5:75 
extract genomic DNA (stored under −20  °C) from 6 
peripheral blood samples of 2 patients.
Count of peripheral white blood cell and detection of C3 
and anti‑nuclear antibody spectrum
Peripheral white blood cell count and detection of C3 
and anti-nuclear antibody spectrum at every time point 
were provided by Medical Laboratory of Zunyi Medical 
University affiliated hospital. The method of peripheral 
white blood cell count was flow type laser impedance 
triple method (full automatic blood cell analyzer assem-
bly line, XE-5000, Sysmex). Method of C3 detection was 
immunoturbidimetry (full automatic special protein ana-
lyzer, IMMAGE800, Beckman). The detecting method of 
antinuclear antibody spectrum was EURO Blot (accord-
ing to standard operating process of the factory).
High‑throughput sequencing
Before high-throughput sequencing, the concentration 
and purity of DNA of samples need to reach the require-
ment of BCR CDR3 sequencing and the volume of every 
sample was the same (the whole total DNA needs to 
reach 2 μg). Multiplexed PCR amplification is performed 
to amplify rearranged CDR3 sequences, designing an 
upstream primer and downstream primer in the VH func-
tional gene region and JH functional gene region, respec-
tively. Every primer was set in the specific site of BCR H 
chain. Error from bias in this multiplexed PCR assay was 
controlled using synthetic templates (Carlson et al. 2013). 
Illumina adaptors are subsequently added for next-genera-
tion sequencing. Amplification and sequencing were com-
pleted by Adaptive Biotechnologies ImmunoSEQ platform 
(http://www.adaptivebiotech.com) (Wu et al. 2014).
Sequence analysis
Raw sequences with FASTA format were submitted to 
IMGT/HighV-QUEST online software (http://www.imgt.
org). IMGT summary file was used to filter sequence 
according to the following principle: (1) No results; (2) 
Unknown; (3) Warnings; (4) Unproductive; (5) V gene 
was pseudogene; (6) AA of 104 position was non-cysteine 
(Cysteine, C) or AA of 118 position was non-tryptophan 
(Tryptophan, W). The analysis and storage of sequences 
were completed in Excel (version 2010) and graph was 
completed by Prism 5 software (GraphPad). The formula 
of inverse Simpson index (1/Ds) was 1/Ds = 1/[1-∑(Ni(Ni-
1))/(N(N-1))], Ni was defined as the frequency of i gene, 
and N was defined as the total number of genes.
Results
Clinical hematology examination
One month after high dose glucocorticoid therapy, the 
number of white blood cell of two SLE patients both 
decreased, and on the third month, the white blood cell 
number rose to the level before treatment (Additional 
file 2: Table S2). After treatment, the clinical manifesta-
tion of two patients turned better, but serumal IgG level 
of P2 decreased evidently while serumal IgG level of P1 
increased. In addition, the serumal antinuclear antibody 
level of two SLE patients had different degree of change 
at three different time points, which reflected serologi-
cal heterogeneity of SLE (Table 1). The antinuclear anti-
body level of two patients both improved, indicating 
that the treatment can partly decrease the expression of 
autoantibody.
Diversity evaluation of BCR repertoire
After the raw data was uploaded to IMGT/HighV-
QUEST, IMGT data was used for analysis after filtration 
(Table  2). The Table  2 shows that the BCR sequences 
from patient P1 decreased evidently after treatment 
while there was no evident change in patient P2. In order 
to evaluate the change of diversity of BCR repertoire, 
we introduced inverse Simpson’s diversity index (1/Ds) 
(Hochberg et  al. 2001). The clone distributions of these 
two SLE patients at three different time points show that 
the initial diversity of P1 before treatment was evidently 
lower than that of P2. The diversity of BCR repertoire of 
P1 after treatment decreased significantly and the clone 
distribution changed evidently, while the diversity of 
BCR repertoire of P2 had no evident change over time. 
These results suggested that the humoral immunity of 
P1 had steady maladjustment, existing the risk of infec-
tion or suffering from other diseases; while the state of 
Table 1 The antinuclear antibodies indexes of  two SLE 
patients at different time points
The “N” represents negative result, the “1+” represents weakly positive result, 
“2+” represents positive result, “3+” represents strong positive result
Antinuclear antibodies P1 P2
Anti-nRNP/SM 3+, 2+, 2+ 3+, 2+, 1+
Anti-SM N, N, N 2+, 1+, N
Anti-SSA 3+, 3+, 3+ 3+, 3+, 3+
Anti-RO-52 N, N, N 3+, 3+, 3+
Anti-SSB N, N, N 1+, N, N
Anti-SCOL-70 N, N, N N, N, N
Anti-JO-1 N, N, N N, N, N
Anti-CENP B N, N, N N, N, N
Anti-dsDNA 3+, 2+, 2+ 1+, N, N
Anti-nucleosome 3+, 3+, 3+ N, N, N
Anti-histone 3+, 1+, 1+ N, N, N
Anti-ribosomal P N, N, N 3+, 3+, 2+
ACA N, N, N N, N, N
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humoral immunity of P2 tended to be stable (Additional 
file 1: Figure S1).
Usage of IGHV gene subgroup
To evaluate the change of IGHV gene frequency of 
SLE patients over time, we calculated the frequency of 
IGHV gene subgroup of two SLE patients at each point 
(Fig. 1). Figure 1 indicated that IGHV gene distributions 
of two SLE patients at different time points were similar 
and the IGHV usage close to C terminal increased evi-
dently. After treatment, only P1 had little change with 
not over 3 % in some gene usages (IGHV4-34, IGHV3-
13, IGHV3-11, and IGHV4-30-4) at the third month 
after treatment. More notably, after treatment, BCR 
repertoires of two SLE patients lost some IGHV gene 
usages. For example, at the first month after treatment, 
P1 patient lost IGHV3-38, IGHV3-25 and IGHV3-7 
usages (Additional file 2: Table S3). At the third month 
after treatment, some new IGHV genes lost, including 
IGHV3-35 and IGHV3-38-3. As for P2 patient, at the 
first month after treatment, no loss of IGHV gene usage 
was observed. However, at the third month after treat-
ment, usages of IGHV3-35 and IGHV3-7 lost (Addi-
tional file  2: Table S3). Surprisingly, at the first month 
after treatment, P1 got some new IGHV usages with low 
frequency, including IGHV3-7 (0.0025  %) and IGHV3-
64D (0.0086  %). Interestingly, these lost genes were all 
from IGHV3 family.
Pairing of IGHV–IGHJ gene
To assess the change of IGHV–IGHJ gene pairing over 
time, we calculated the frequencies of IGHV–IGHJ pair-
ing of them at three time points (Fig.  2). The heat map 
in Fig.  2 indicated that IGHV–IGHJ gene pairing of 
P1 and P2 had no evident change at three time points 
(Fig.  2). It was worth noting that P1 and P2 had some 
similar dominant pairing (yellow grid area), namely, 
IGHV3-11-IGHJ4, IGHV3-11-IGHJ6, IGHV3-23-IGHJ4, 
IGHV3-30-IGHJ4, IGHV3-30-IGHJ6, IGHV4-30-2-
IGHJ4, IGHV4-34-IGHJ4 and IGHV4-30-2-IGHJ6.
Composition of H‑CDR3
We analyzed the composition change of unique H-CDR3 
over time, including H-CDR3 length distribution and 
H-CDR3 AA usage. The change of H-CDR3 length distri-
bution of two SLE patients is showed in Additional file 1: 
Figure S2. H-CDR3 length distribution of P1 was similar 
between pre-therapy and 1  month after treatment, but 
was evidently changed at the third month, reflecting that 
H-CDR3 longer than 15 AA increased (Additional file 1: 
Figure S2A). It was reported that the longer H-CDR3 
may be related to autoimmune response (Ichiyoshi and 
Casali 1994; Ditzel et  al. 1996; Wardemann et  al. 2003). 
As for P2 patient, we observed that H-CDR3 length dis-
tributions at different time points nearly had no change 
(Additional file  1: Figure S2B). The AA usage of unique 
H-CDR3 of two SLE patients at different time points had 
no evident change (Additional file  1: Figure S3). There-
fore, we further investigated the AA usages of different 
positions (105–117, according to IMGT unique number-
ing) of H-CDR3 with the same length. Figure 3 indicated 
that the AA usages of different positions of the longest 
H-CDR3 (14 AA) at different time points had no evident 
change. H-CDR3 AA composition of SLE patients nearly 
had no change after treatment, indicating that during this 
period time, these two SLE patients barely had new spe-
cific B cell response.
Screening of autoantibody clone
The occurrence of large amount polyclonal autoantibod-
ies is the key factor that results in pathopoiesis of SLE, 
therefore, autoantibody clone set should be considered 
as the commendable treatment target. In order to screen 
the potential autoantibody clones from BCR repertoire of 
two SLE patients, we downloaded all the known autoan-
tibody IGH sequences from IMGT/LIGM-DB database, 
and investigated the sequence number from BCR reper-
toire of two SLE patients that had the same IGHV, IGHJ 
and H-CDR3 AA length with the known autoantibody 
(Table 3; Zhang et al. 2013). Because of the existence of 
SHM, it is difficult to confirm the difference of H-CDR3 
AA. Therefore, the screening condition was not limited 
to the same H-CDR3 AA sequence. Table 3 indicated that 
number of potential autoantibody clones of P1 decreased 
evidently after treatment while number and proportion 
of potential autoantibody clones of P2 maintained in a 
relatively steady level. It was worth noting that, although 
the diversity of BCR repertoire of P1 reduced evidently 
after treatment, however, the proportion of potential 
autoantibody clones did not decrease. Considering that 
Table 2 The sequence data of two SLE patients at different 
time points
Data in brackets is unique
Patients  
no.




P1-0 1105330 (27206) 493579 (14212) 13949
P1-1 579487 (12468) 255209 (6342) 6180
P1-3 366474 (7574) 151170 (3927) 3865
P2-0 1079045 (53222) 470328 (28027) 27729
P2-1 1176658 (53203) 526024 (28160) 27888
P2-3 1037150 (40748) 465958 (21349) 21077
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autoantibody clones is preferentially selected in SLE, the 
affinity of clone with lower frequency may be relatively 
lower. Therefore, we further filtered in the sequences 
with clone no. ≥50 from these potential autoantibody 
clones (Additional file 2: Table S4), these sequences were 
the putative autoantibody clones (Additional file 3: Puta-
tive autoantibody clones). Interestingly, the diversity of 
BCR repertoire of P1 was evidently less than that of P2, 
but the number of putative autoantibody clones of P1 
(recurrence) was evidently more than that of P2 (primary 
attack).
Discussion
BCRs develop with the growth and differentiation of B 
cells. VDJ rearrangement of BCR heavy chain initially 
appears in pre-B stage of marrow. After immature B 
cells leaving marrow and entering into the periphery, 
some migrating B cells differentiate into immature 
naïve B cells and further differentiate into mature naïve 
B cells. The mature naïve B cells go through SHM under 
antigen stimulation and finally differentiated into mem-
ory B cells or plasmocyte secreted antibody. In normal 
body, this process will not produce autoreactive B cell 
and autoantibody. However, as for SLE patients, many 
factors result in the occurrence of autoreactive B cell 
and autoantibody, including abnormal growth and tol-
erance of B cell, abnormal activity of B cell and abnor-
mal apoptosis of autoreactive B cell (Renaudineau et al. 
2004).
In the past, the technological means to study on 
BCR repertoire of SLE patients mainly relied on 
polymerase chain reaction (PCR)-single strand 
Fig. 1 Known alleles for each of the mapped and unmapped IGHV genes are arranged according to IMGT/HighV-QUEST Statistical Analysis Report. 
And IGHV genes usage of two SLE patients is calculated as the percentage of the total analyzed sequences. a P1-0, P1-1 and P1-3; b P2-0, P2-1 and 
P2-3
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Fig. 2 Frequencies of specific IGHV and IGHJ gene pairing in two SLE patients at different time points are depicted. IGHJ genes are indicated on the 
left, IGHV genes at the bottom of the panels. Total reads (%) of a given pairing are indicated by color code. P1 and P2 show restricted usage of IGHV 
and IGHJ genes. a P1-0, P1-1 and P1-3. b P2-0, P2-1 and P2-3
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conformation polymorphism analysis (SSCP), flow 
cytometry and immune spectratyping. Limited by 
number of sequence data, these past methods were 
hard to reflect BCR repertoire. High dose glucocor-
ticoid treatment is the most basic treatment plan 
for SLE patient at the active stage. However, its side 
effect is very extreme, so many researchers focus 
on targeted treatment. In the past, it was generally 
thought that pathopoiesis of SLE was related to T 
cells and the remission of SLE was related to normal 
immune reconstitution. However, the current view 
suggests that autoreactive B cells and autoantibodies 
are the key factors of pathopoiesis of SLE (Arbuckle 
et  al. 2003); meanwhile, B cells are also considered 
as the main target of SLE treatment (Shlomchik et al. 
2001; Sanz and Lee 2010). Taken together, these rea-
sons prompt us to use high-throughput sequenc-
ing to investigate the BCR repertoire of SLE patients 
after high dose glucocorticoid treatment and screen 
autoantibody clones.
In this study, we analyzed the composition change 
of BCR repertoire of two SLE patients after treat-
ment in various angles. In the gene usage, we found 
that there were some losses of IGHV usages in P1 
after treatment, including IGHV3-38, IGHV3-25, 
IGHV3-7, IGHV3-35 and IGHV3-38-3. As for P2, 
Fig. 3 The frequency of individual amino acids at specific positions (105–117) for the most prevalent H-CDR3 sequences having the length of 
14 amino acids (the basic length of CDR3-IMGT) in each SLE patient is shown. The color menu for amino acids is according to IMGT (Ruiz and 
Lefranc 2000). H-CDR3 positions are shown according to the IMGT unique numbering. Arabic numerals (0, 1, 3) in the brackets at the bottom of the 
panels respectively represent three time points. a P1-0 (n = 1674), P1-1 (n = 762) and P1-3 (n = 456). b P2-0 (n = 3060), P2-1 (n = 3200) and P2-3 
(n = 2423)
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although there were two new gene expressions with 
low frequency [IGHV3-7 (0.0025 %) and IGHV3-64D 
(0.0086  %)] at the first month after treatment, there 
were still losses of IGHV3-35 and IGHV3-7 gene at 
the third month after treatment. It was worth noting 
that the lost two genes of P2 were also in the range 
of lost gene of P1. Although the frequencies of these 
lost genes are low, some genes with lower frequency 




IGHVs IGHJs CDR3  
length
P1‑0 P1‑1 P1‑3 P2‑0 P2‑1 P2‑3
AF035024 IGHV3-30 IGHJ4 6 AA 87 0 0 75 156 36
AF035021 IGHV3-30 IGHJ4 10 AA 1060 375 303 802 896 1353
L12105 IGHV1-2 IGHJ4 10 AA 14 36 38 136 379 227
AF035023 IGHV3-48 IGHJ3 11 AA 65 42 50 58 127 40
L12087 IGHV1-3 IGHJ4 11 AA 416 238 115 371 312 217
AF035020 IGHV3-48 IGHJ3 12 AA 235 0 198 95 183 96
AF035042 IGHV3-53 IGHJ4 12 AA 995 150 102 426 482 664
L12100 IGHV1-2 IGHJ6 12 AA 81 0 0 131 43 159
X54435 IGHV3-74 IGHJ5 12 AA 18 147 0 22 44 89
AF035018 IGHJ2-5 IGHJ4 13 AA 712 354 95 1471 850 792
AF035025 IGHV1-69 IGHJ2 13 AA 0 0 0 39 56 61
AF035041 IGHV4-59 IGHJ4 13 AA 961 248 362 1176 1393 1406
D16837 IGHV1-69 IGHJ4 13 AA 658 206 165 504 815 695
L12061 IGHV1-2 IGHJ4 13 AA 122 80 85 695 631 674
L12102 IGHV1-3 IGHJ4 13 AA 588 360 188 411 440 327
AF035043 IGHV3-43 IGHJ3 14 AA 76 35 77 131 114 126
L12090 IGHV3-53 IGHJ6 14 AA 180 0 113 148 84 116
L12098 IGHV1-3 IGHJ4 14 AA 743 419 138 598 437 449
X73856 IGHV1-8 IGHJ6 14 AA 88 0 0 55 99 160
AF035030 IGHV3-30 IGHJ4 15 AA 2939 1426 828 2052 2534 2339
S73912 IGHV3-21 IGHJ4 15 AA 5 0 0 0 0 0
M85255 IGHV3-30 IGHJ6 16 AA 1878 949 896 1225 1178 1138
U07194 IGHV1-2 IGHJ5 16 AA 50 0 24 163 84 85
AF035022 IGHV1-46 IGHJ4 17 AA 305 123 0 103 284 230
AF035040 IGHV6-1 IGHJ3 17 AA 0 0 162 36 19 0
L12096 IGHV1-69 IGHJ3 17 AA 44 33 23 175 167 164
U07196 IGHV4-61 IGHJ3 17 AA 0 0 0 0 0 0
X73851 IGHV1-2 IGHJ3 17 AA 0 29 5 147 93 126
X73857 IGHV4-31 IGHJ4 17 AA 160 98 204 0 0 0
AF035019 IGHV1-2 IGHJ3 18 AA 0 0 0 60 102 85
AF035027 IGHV3-9 IGHJ1 18 AA 0 0 0 8 24 8
X15611 IGHV1-18 IGHJ4 18 AA 382 154 13 300 277 228
D16833 IGHV3-74 IGHJ2 21 AA 0 0 0 0 0 29
X54445 IGHV4-4 IGHJ4 21 AA 0 0 0 0 0 0
X56592 IGHV4-34 IGHJ4 21 AA 265 95 122 321 170 371
X73859 IGHV3-23 IGHJ6 21 AA 517 200 75 403 583 329
AF035026 IGHV3-15 IGHJ4 22 AA 81 58 5 31 20 10
D84252 IGHV3-33 IGHJ6 22 AA 147 121 0 0 0 0
U07195 IGHV4-34 IGHJ5 22 AA 49 10 0 157 173 100
Total no. 13,921 5986 4386 12,525 13,249 12,929
Percent (%) 2.82 2.35 2.90 2.66 2.52 2.77
Page 9 of 10Shi et al. SpringerPlus  (2016) 5:75 
can be detected at each time point. Although these 
two SLE patients had some losses of gene usages, 
the number of these genes was not over 100. Such 
an amount of scale was very small for BCR reper-
toire. When we investigated the change of IGHV–
IGHJ gene pairing over time, these two SLE patients 
had striking similarity, which no evident change was 
observed in IGHV–IGHJ pairing at each time point. 
In addition, analyses of the composition of H-CDR3 
showed overall AA compositions of H-CDR3 at three 
time points in each SLE patient were very similar, and 
the results of H-CDR3 AA usage that had the same 
length (14 AA) and the same position were similar. 
These results support one possibility that this treat-
ment will barely affect the composition of SLE 
patients’ BCR repertoire in a short term.
Moreover, we have investigated the antinuclear 
antibodies indexes of these two SLE patients. The 
expression of some antinuclear antibodies of two SLE 
patients had decreased after treatment, suggesting 
the treatment could definitely reduce the formation 
of autoantibody protein. However, when we screened 
autoantibody clones, the proportion of potential 
autoantibody clones of two SLE patients did not shown 
any decreasing sign. That is, the treatment can reduce 
the formation of autoantibody in the protein level, but 
may not reduce the proportion of autoantibody clone 
in BCR repertoire in the clone level. In the past, we 
could say that the relief of SLE patients was related to 
normal immune reconstitution. But now, we must be 
cautious with this, because our result indicates that the 
BCR repertoire of these two SLE patients did not turn 
better. This finding can roughly explain the clinical fea-
ture that SLE can easily recur.
In brief, this study has done a short-term analysis 
and evaluation on BCR repertoire of two SLE patients 
after high dose glucocorticoid treatment, and this 
may provide new idea for the immunologic surveil-
lance and treatment of SLE. Moreover, autoantibody 
sequences that we screened can provide reference for 
other functional experiments. Finally, we propose that 
this analysis and evaluation of BCR repertoire can be 
applied to more other immunologic diseases.
Conclusion
In this study, our results suggested that high dose glu-
cocorticoid treatment can reduce the formation of 
autoantibody in the protein level, but may not reduce the 
proportion of autoantibody clone in BCR repertoire in 
the clone level. In addition, the treatment in short term 
may have little impact on compositon of BCR repertoire 
of SLE patient.
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